NCT04647539: EIFI

Emerging Invasive Fungal Infections in Critically Ill Patients

Completed Last updated 1 December 2020

What this trial tests

trial in Fungal Infection in 26 participants. Completed in 23 November 2020.

Timeline

1 January 2006

Primary endpoint
1 December 2019

23 November 2020

Quick facts

Lead sponsor	University Hospital, Montpellier
Status	Completed
Study type	OBSERVATIONAL
Enrollment	26
Start date	1 January 2006
Primary completion	1 December 2019
Estimated completion	23 November 2020
Sites	1 location across France

Conditions studied

• Fungal Infection — all drugs for Fungal Infection →
• ICU Acquired Weakness — all drugs for ICU Acquired Weakness →

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 99, any sex, with Fungal Infection or ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are increasing in intensive care setting and are associated with high morbidity and mortality. However, data are scarce, particularly in ICU settings and for EIFIs other than mucormycosis.

Objectives: to describe epidemiological trends and clinical features of EIFIs in intensive care units (ICU) and to assess their outcome.

Methods: All records of adult patients diagnosed with an EIFI in a medical ICU between 2006 and 2019 were analyzed retrospectively. In-ICU mortality was assessed, then factors associated with mortality were identified. Survival at day-90 was calculated by the Kaplan-Meier method.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Emerging Invasive Fungal Infections in Critically Ill Patients: Incidence, Outcomes and Prognosis Factors, a Case-Control Study.
   Larcher R, Platon L, Amalric M, Brunot V, et al · · 2021 · cited 11× · PMID 33923333 · DOI 10.3390/jof7050330